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http://dx.doi.org/10.1016/j.jmii.2012Purpose: The purpose of this study was to determine the distribution and changes in the anti-
biotic susceptibilities of uropathogens isolated from adults with community-acquired urinary
tract infections (CA-UTIs) in Crete, Greece, over a 6-year period.
Methods: This study was performed with isolates from outpatients with UTIs, collected
between 2005 and 2010. Isolates were identified by standard methods and antimicrobial
susceptibility testing was performed using the disk diffusion method and the VITEK2 is an auto-
mated system used for identification and antimicrobial susceptibility testing of microorganisms
(BioMerieux). To identify changes in susceptibility patterns, we compared results of the period
2005e2007 to those of the period 2008e2010. We also compared the antibiotic susceptibilities
of isolates between males and females.
Results: A total of 4011 community-acquired uropathogens were isolated during the period of
2005e2010. Escherichia coli was the most common organism and responsible for 68.9% of CA-
UTIs, followed by Proteus mirabilis (6.8%), Klebsiella pneumoniae (6.4%) and enterococci (6%).
A significant increase in resistance of E coli isolates was noted for b-lactams, monobactams,
aminoglycosides, quinolones, and cotrimoxazole. The reverse trend was evident for nitrofuran-
toin. Higher resistance rates of community-acquired E coli and non-E coli Enterobacteriaceae
were noted in males for ampicillin, amoxicillin plus clavulanic acid, cephalosporins, aminogly-
cosides, and quinolones. No significant sex differences were noted in the antibiotic suscepti-
bility patterns of enterococci.
Conclusion: There is a concerning trend for increasing resistance among E coli and non-E coli
Enterobacteriaceae responsible for CA-UTIs in Crete in recent years likely due to theof Clinical Microbiology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of
reece.
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Antibiotic susceptibility of uropathogens 203inappropriate use of broad spectrum antibiotics, as a substitute for precise diagnostics and/or
to increase the chances of therapeutic success.
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Introduction
To optimize the use of empirical antibacterial therapy for
community acquired urinary tract infections (CA-UTIs),
physicians should know the etiology and susceptibility
patterns of urinary pathogens in their community.
Most CA-UTIs reflect episodes of acute, uncomplicated
cystitis. The Infectious Diseases Society of America (IDSA)
guidelines for the treatment of acute uncomplicated
cystitis in women recommend the use of a 3-day course of
cotrimoxazole as empiric first-line therapy except in
communities with resistance rates exceeding 10%e20% to
cotrimoxazole among uropathogens.1 Although the rela-
tionship between antibiotic consumption and resistance is
complex and some studies show no significant change in
antimicrobial susceptibility over time,2 increased antibiotic
use and inappropriate use of newer broad spectrum anti-
biotics due to the fear of therapeutic failure with older
agents, selects for resistant organisms, and antibiotic
resistance is increasing among community-acquired urinary
pathogens worldwide.3e5
The University Hospital of Heraklion is the only tertiary
hospital in the island of Crete, Greece, and serves a pop-
ulation of more than 700,000 people. In this study, we
describe the in vitro antimicrobial susceptibility patterns of
community-acquired uropathogens that were isolated in
the microbiology laboratory of this hospital over the period
January 2005 to December 2010.
Materials and methods
Patients
The patients of this study were adult (age >14 years) outpa-
tients of both sexes diagnosed and treated for CA-UTIs in one
of the several outpatient clinics of the University Hospital of
Heraklion.AUTIwasconsideredascommunity-acquired if the
patient had not received intravenous therapy or specialized
wound care, had not received hemodialysis treatment or
antineoplastic chemotherapy within the 30 days prior to
infection, was not hospitalized in an acute care center the
last 90 days before diagnosis of UTI, and did not reside in
a nursing home or long-term care facility.6 Patients with
urinary catheters were excluded, since by definition they
were considered as having healthcare-associated or nosoco-
mial UTIs. All urine samples were collected in the emergency
room or in one of the outpatient clinics of the hospital.
Duplicatepositive urine cultures, i.e., cultures fromthe same
episode of UTI were excluded.
Laboratory methods
Quantitative urine cultures were performed with standard
techniques using Columbia blood and MacConkey agar plates(BioMe´rieux, Marcy l’ Etoile, France). Plates were incu-
bated for 18e24 hours at 36C. Isolate identification was
done by standard biochemical methods, the API system, and
the VITEK2 automated system (BioMe´rieux). Antimicrobial
susceptibility testing was performed using the disk diffusion
method and the VITEK2 automated system.
The following antibiotics were tested against Gram-
negative isolates: ampicillin, amoxicillin plus clavulanic
acid (CA), ticarcillin, ticarcillin plus CA, piperacillin,
piperacillin/tazobactam, cephalothin, cefoxitin, cefurox-
ime, cefotaxime, ceftriaxone, ceftazidime, cefepime,
aztreonam, imipenem, tobramycin, amikacin, gentamicin,
netilmicin, tetracycline, colistin, cotrimoxazole, nitro-
furantoin, nalidixic acid, pefloxacin, ofloxacin, norfloxacin,
and ciprofloxacin. Double-disk synergy test was used for
preliminary classification of the isolates as extended-
spectrum b-lactamase (ESBL) producers. The synergistic
activity of CA with both ceftazidime and cefotaxime was
confirmed by means of E-test special strips (AB Biodisk,
Solna, Sweden) containing ceftazidime/ceftazidime plus CA
and cefotaxime/cefotaxime plus CA.8
The following antibiotics were tested against entero-
cocci: Ampicillin, ampicillin plus sulbactam, gentamicin
[high level (HL) resistance], tetracycline, nitrofurantoin,
ciprofloxacin, vancomycin, and teicoplanin. Quality control
strains used for antimicrobial susceptibility testing included
E coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853,
K pneumoniae ATCC 700603 (ESBL producer), and Entero-
coccus faecalis ATCC 29212. Results were interpreted
according to the Clinical and Laboratory Standards Institute
(CLSI) criteria.8
Statistical analysis
The proportion of resistant organisms was calculated by
dividing the number of urinary isolates resistant to each
antibiotic by the number of organisms that were tested
against that antimicrobial agent. Intermediately resistant
and resistant organisms were grouped together. To test for
changes in the antibiotic susceptibilities of uropathogens
over time, Fisher’s exact test was used to compare the
antibiotic susceptibilities of E coli, non-E coli Enter-
obacteriaceae, and Enterococcus spp. between the first
(1/2005-12/2007) and second half of the study period
(1/2008-12/2010), and between males and females. All
tests were two-tailed and statistical significance was set at
p values < 0.05. Statistical analysis was performed by
Graphpad Prism software (version 4, La Jolla, CA, USA).
Results
A total of 4011 uropathogens were isolated during the
period of January 2005 to December 2010 from patients
with CA-UTIs. The distribution of urinary pathogens by
Table 1 Distribution of community-acquired uropathogens by study year (2005e2010)
2005 2006 2007 2008 2009 2010 2005e2010
Escherichia coli 393 (70.6%) 468 (68.9%) 430 (70.6%) 400 (63.4%) 537 (71.6%) 534 (68%) 2762 (68.9%)
Proteus mirabilis 34 (6.1%) 51 (7.5%) 34 (5.6%) 44 (7%) 57 (7.6%) 53 (6.8%) 273 (6.8%)
Proteus vulgaris d 1 (0.2%) d 1 (0.2%) d d 2 (0.05%)
Proteus penneri d 1 (0.2%) 1 (0.2%) d d d 2 (0.05%)
Klebsiella pneumoniae 21 (3.8%) 32 (4.7%) 32 (5.2%) 47 (7.4%) 46 (6.1%) 75 (9.6%) 253 (6.3%)
Klebsiella oxytoca 2 (0.4%) 5 (0.7%) 3 (0.5%) 7 (1.1%) 2 (0.3%) 4 (0.5%) 23 (0.6%)
Enterobacter spp. 12 (2.1%) 12 (1.8%) 14 (2.3%) 10 (1.5%) 8 (1.1%) 13 (1.7%) 69 (1.7%)
Citrobacter spp. 7 (1.2%) 7 (1%) 12 (2%) 14 (2.2%) 9 (1.2%) 15 (1.9%) 64 (1.6%)
Morganella morganii 2 (0.4%) 2 (0.3%) d d 4 (0.5%) 3 (0.4%) 11 (0.3%)
Serratia spp. 2 (0.4%) d 2 (0.3%) d 1 (0.1%) 4 (0.5%) 9 (0.2%)
Salmonella spp. d 2 (0.3%) d d d 1 (0.1%) 3 (0.07%)
Pseudomonas aeruginosa 18 (3.2%) 15 (2.2%) 10 (1.6%) 19 (3%) 16 (2.1%) 11 (1.4%) 89 (2.2%)
Other gram-negative
nonfermenters
2 (0.4%) 3 (0.4%) 2 (0.3%) 3 (0.5%) 5 (0.7%) 1 (0.1%) 16 (0.4%)
Enterococcus faecalis 31 (5.6%) 42 (6.2%) 40 (6.5%) 43 (6.8%) 35 (4.7%) 38 (4.8%) 229 (5.7%)
Enterococcus faecium 2 (0.4%) 2 (0.3%) 1 (0.2%) 1 (0.2%) 4 (0.5%) 3 (0.4%) 13 (0.3%)
Streptococcus agalactiae 6 (1%) 13 (1.9%) 6 (1%) 17 (2.7%) 11 (1.5%) 12 (1.5%) 65 (1.6%)
Streptococcus pyogenes d 1 (0.2%) 1 (0.2%) 1 (0.2%) d d 3 (0.07%)
Staphylococcus aureus 3 (0.5%) 2 (0.3%) d 6 (1%) 1 (0.1%) d 12 (0.3%)
Staphylococcus coag. negative 3 (0.5%) 5 (0.7%) 2 (0.3%) 4 (0.6%) 3 (0.4%) 3 (0.4%) 20 (0.5%)
Staphylococcus saprophyticus 19 (3.4%) 15 (2.2%) 18 (3%) 14 (2.2%) 11 (1.5%) 15 (1.9%) 92 (2.3%)
Corynebacterium spp. d d 1 (0.2%) d d d 1 (0.02%)
Total 557 679 609 631 750 785 4011
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most common organism and responsible for 68.9% of CA-
UTIs in this study, followed by P mirabilis (6.8%), K pneu-
moniae (6.4%), and enterococci (6%, E faecalis 5.7%,
E faecium 0.3%). As shown in Table 2, a significant increase
in resistance of E coli isolates was noted between the two
study periods for monobactams (aztreonam) and all b-
lactam antibiotics tested except ticarcillin plus CA,
a parenteral antibiotic that is available only for nosocomial
use. The same was true for aminoglycosides with the
exception of gentamicin in which the increased resistance
rate over the second period did not reach statistical
significance, and amikacin in which a borderline decrease
in resistance in recent years was noted. Regarding quino-
lones, a significant increase in nonsusceptibility was noted
during the second half of the study. Concerning cotrimox-
azole, a commonly used antibiotic for uncomplicated CA-
UTIs, a significant increase in resistance was noted from
20.2% during the years 2005e2007 to 24% during the period
of 2008e2010 (pZ 0.0172). On the other hand, the reverse
trend was evident for nitrofurantoin, an infrequently used
antibiotic in Greece, in which the resistance rate dropped
for 9.1% to 4.2% between the first and the second half of
the study period. The only three non-b-lactam antibiotics
for which no significant change in resistance was noted
between the two study periods were imipenem, tetracy-
cline and colistin. Regarding the other Enterobacteriaceae,
no significant increase in resistance to ampicillin and
amoxicillin plus CA was noted between the first and second
half of the study period, but the resistance rates were high
in both periods. A significant increase in resistance of these
uropathogens was also noted against the antipseudomonalpenicillins ticarcillin, ticarcillin plus CA, piperacillin, and
piperacillin/tazobactam. The same trend of increased
resistance was noted for all tested cephalosporins except
cephalothin, a first generation cephalosporin and cefoxitin,
a cephamycin often grouped with the second-generation
cephalosporins. A significant increase in resistance of the
other Enterobacteriaceae was noted against all tested
aminoglycosides, cotrimoxazole and all tested quinolones
except nalidixic acid and pefloxacin in which the increased
resistance rates over the period 2008e2010 did not reach
statistical significance. As was noted with E coli isolates,
a decrease in resistance rates to nitrofurantoin of non-E
coli Enterobacteriaceae was noted over the years
2008e2010. Moreover, the other Enterobacteriaceae were
significantly less susceptible to aztreonam and imipenem in
recent years.
Regarding ESBL producing strains of E coli, a significant
increase was noted between the first (22 of 1291, 1.7%) and
second (51 of 1271, 3.5%) half of the study (pZ 0.0005). About
ESBL producing strains of Klebsiella spp., an increase was
noted between the two periods from 5.3% (5 of 95) in
2005e2007 to 12.3% (23 of 181, pZ 0.00596) in 2008e2010.
Finally, three ESBL producing strains of P mirabiliswere seen,
all in the more recent years (two in 2009 and one in 2010).
Regarding enterococci (E faecalis and E faecium), no
significant changes in antibiotic resistance were noted
between the two study periods for ampicillin with or
without sulbactam, tetracycline, nitrofurantoin, and
ciprofloxacin. On the other hand, gentamicin-HL resistance
was substantially lower in recent years, while enterococci
resistant to glycopeptides were noted only during the
period 2005e2007.
Table 2 Antibiotic susceptibilities by study year for E coli, non-E coli Enterobacteriaceae and Enterococci
E coli
Antimicrobial
agent
2005, nZ 393
Resistant
2006,nZ 468
Resistant
2007,nZ 430
Resistant
2008,nZ 400
Resistant
2009,nZ 537
Resistant
2010,nZ 534
Resistant
2005e07 (A),
nZ 1291
Resistant
2008e10 (B),
nZ 1471
Resistant
p value A
vs. B
Ampicillin 143 (36.4%) 150 (32.1%) 173 (40.2%) 151 (37.7%) 252 (46.9%) 212 (39.7%) 466 (36.1%) 615 (41.8%) 0.0023
Amoxicillin plus CA 57 (14.5%) 60 (12.8%) 57 (13.3%) 60 (15%) 115 (21.4%) 81 (15.2%) 174 (13.5%) 256 (17.4%) 0.0045
Ticarcillin 138 (35.1%) 146 (31.2%) 167 (38.8%) 139 (34.7%) 227 (42.3%) 203 (38%) 451 (34.9%) 569 (38.7%) 0.0439
Ticarcillin plus CA 81 (20.6%) 59 (12.6%) 86 (20%) 65 (16.2%) 129 (24%) 80 (15%) 226 (17.5%) 274 (18.6%) 0.4578
Piperacillin 122 (31%) 146 (31.2%) 164 (38.1%) 135 (33.7%) 224 (41.7%) 193 (36.1%) 432 (33.5%) 552 (37.5%) 0.0285
Piperacillin/
tazobactam
17 (4.3%) 13 (2.8%) 15 (3.5%) 14 (3.5%) 41 (7.6%) 39 (7.3%) 45 (3.5%) 94 (6.4%) 0.0005
Cephalothin 146 (37.2%) 159 (34%) 160 (37.2%) 117 (29.2%) 188 (35%) 146 (27.3%) 465 (36%) 451 (30.7%) 0.0031
Cefoxitin 7 (1.8%) 15 (3.2%) 15 (3.5%) 11 (2.7%) 27 (5%) 35 (6.6%) 37 (2.9%) 73 (5%) 0.0061
Cefuroxime 11 (2.8%) 21 (4.5%) 19 (4.4%) 20 (5%) 41 (7.6%) 44 (8.2%) 51 (4%) 105 (7.1%) 0.0003
Cefotaxime 7 (1.8%) 9 (1.9%) 7 (1.6%) 7 (1.7%) 24 (4.5%) 21 (3.9%) 23 (1.8%) 52 (3.5%) 0.0047
Ceftriaxone 7 (1.8%) 9 (1.9%) 7 (1.6%) 7 (1.7%) 24 (4.5%) 21 (3.9%) 23 (1.8%) 52 (3.5%) 0.0047
Ceftazidime 7 (1.8%) 9 (1.9%) 7 (1.6%) 7 (1.7%) 24 (4.5%) 21 (3.9%) 23 (1.8%) 52 (3.5%) 0.0047
Cefepime 7 (1.8%) 9 (1.9%) 7 (1.6%) 7 (1.7%) 24 (4.5%) 21 (3.9%) 23 (1.8%) 52 (3.5%) 0.0047
Imipenem 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.2%) 0 (0%) 0 (0%) 1 (0.1%) 1
Aztreonam 7 (1.8%) 9 (1.9%) 7 (1.6%) 7 (1.7%) 24 (4.5%) 21 (3.9%) 23 (1.8%) 52 (3.5%) 0.0047
Tobramycin 11 (2.8%) 4 (0.8%) 16 (3.7%) 9 (2.3%) 31 (5.8%) 32 (6%) 31 (2.4%) 72 (4.9%) 0.0006
Amikacin 17 (4.3%) 21 (4.5%) 9 (2.1%) 5 (1.3%) 16 (3%) 14 (2.6%) 47 (3.6%) 35 (2.4%) 0.0562
Gentamicin 16 (4.1%) 13 (2.8%) 14 (3.2%) 10 (2.5%) 28 (5.2%) 27 (5.1%) 43 (3.3%) 65 (4.4%) 0.1682
Netilmicin 7 (1.8%) 3 (0.6%) 14 (3.2%) 9 (2.3%) 29 (5.4%) 26 (4.9%) 24 (1.9%) 64 (4.4%) 0.0002
Tetracycline 85 (21.6%) 116 (24.8%) 102 (23.7%) 101 (25.3%) 148 (27.6%) 116 (21.7%) 303 (23.5%) 365 (24.8%) 0.4230
Colistin 1 (0.2%) 1 (0.2%) 0 (0%) 1 (0.3%) 0 (0%) 1 (0.2%) 2 (0.2%) 2 (0.1%) 0.6279
Cotrimoxazole 78 (19.8%) 91 (19.4%) 92 (21.4%) 85 (21.3%) 143 (26.6%) 125 (23.4%) 261 (20.2%) 353 (24%) 0.0172
Nitrofurantoin 51 (13%) 46 (9.8%) 21 (4.9%) 17 (4.3%) 25 (4.7%) 20 (3.7%) 118 (9.1%) 62 (4.2%) 0.0001
Nalidixic acid 22 (5.6%) 39 (8.3%) 50 (11.6%) 34 (8.5%) 84 (15.6%) 67 (12.5%) 111 (8.6%) 185 (12.6%) 0.0008
Pefloxacin 20 (5.1%) 33 (7%) 40 (9.3%) 32 (8%) 68 (12.7%) 54 (10.1%) 93 (7.2%) 154 (10.5%) 0.0026
Ofloxacin 15 (3.8%) 26 (5.5%) 33 (7.7%) 24 (6%) 56 (10.4%) 50 (9.4%) 74 (5.7%) 130 (8.8%) 0.0021
Norfloxacin 17 (4.3%) 26 (5.5%) 33 (7.7%) 26 (6.5%) 57 (10.6%) 53 (9.9%) 76 (5.9%) 136 (9.2%) 0.0016
Ciprofloxacin 16 (4.1%) 25 (5.3%) 33 (7.7%) 24 (6%) 53 (9.9%) 52 (9.7%) 74 (5.7%) 129 (8.8%) 0.0027
Non-E coli Enterobacteriaceae
Antimicrobial
agent
2005, nZ 80
Resistant
2006, nZ 114
Resistant
2007, nZ 98
Resistant
2008, nZ 122
Resistant
2009, nZ 127
Resistant
2010, nZ 168
Resistant
2005e07 (A),
nZ 292
Resistant
2008e10 (B),
nZ 417
Resistant
p value A
vs. B
Ampicillin 55 (68.7%) 81 (71.1%) 26 (26.5%) 94 (77%) 97 (76.4%) 35 (20.8%) 162 (55.5%) 226 (54.2%) 0.7594
Amoxicillin plus CA 24 (30%) 23 (20.2%) 22 (22.4%) 27 (22.1%) 43 (33.9%) 51 (30.4%) 69 (23.6%) 121 (29%) 0.1212
Ticarcillin 41 (51.2%) 67 (58.8%) 59 (60.2%) 83 (68%) 89 (70.1%) 115 (68.5%) 167 (57.2%) 287 (68.8%) 0.0019
Ticarcillin plus CA 11 (13.7%) 11 (9.6%) 13 (13.3%) 18 (14.7%) 29 (22.8%) 30 (17.9%) 35 (12%) 77 (18.5%) 0.0213
Piperacillin 34 (42.5%) 64 (56.1%) 55 (56.1%) 83 (68%) 86 (67.7%) 112 (66.7%) 153 (52.4%) 281 (67.4%) 0.0001
(continued on next page)
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Table 2 (continued )
Non-E coli Enterobacteriaceae
Antimicrobial
agent
2005, nZ 80
Resistant
2006, nZ 114
Resistant
2007, nZ 98
Resistant
2008, nZ 122
Resistant
2009, nZ 127
Resistant
2010, nZ 168
Resistant
2005e07 (A),
nZ 292
Resistant
2008e10 (B),
nZ 417
Resistant
p value A
vs. B
Piperacillin/
tazobactam
5 (6.2%) 8 (7%) 6 (6.1%) 14 (11.5%) 22 (17.3%) 24 (14.3%) 19 (6.5%) 60(14.4%) 0.0010
Cephalothin 26 (32.5%) 34 (29.8%) 28 (28.6%) 35 (28.7%) 43 (33.8%) 55 (32.7%) 88 (30.1%) 133 (31.9%) 0.6805
Cefoxitin 18 (22.5%) 18 (15.8%) 23 (23.5%) 22 (18%) 30 (23.6%) 44 (26.2%) 59 (20.2%) 96 (23%) 0.4064
Cefuroxime 12 (15%) 15 (13.2%) 14 (14.3%) 20 (16.4%) 29 (22.8%) 39 (23.2%) 41 (14%) 88 (21.1%) 0.0176
Cefotaxime 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 21 (16.5%) 20 (11.9%) 15 (5.1%) 52 (12.5%) 0.0010
Ceftriaxone 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 21 (16.5%) 20 (11.9%) 15 (5.1%) 52 (12.5%) 0.0010
Ceftazidime 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 21 (16.5%) 20 (11.9%) 15 (5.1%) 52 (12.5%) 0.0010
Cefepime 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 21 (16.5%) 20 (11.9%) 15 (5.1%) 52 (12.5%) 0.0010
Imipenem 0 (0%) 1 (0.9%) 0 (0%) 8 (6.6%) 7 (5.5%) 5 (3%) 1 (0.3%) 20 (4.8%) 0.0004
Aztreonam 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 21 (16.5%) 20 (11.9%) 15 (5.1%) 52 (12.5%) 0.0010
Tobramycin 4 (5%) 7 (6.2%) 7 (7.1%) 12 (9.8%) 19 (15%) 19 (11.3%) 18 (6.2%) 50 (12%) 0.0095
Amikacin 5 (6.2%) 3 (2.6%) 7 (7.1%) 10 (8.2%) 17 (13.4%) 19 (11.3%) 15 (5.1%) 46 (11%) 0.0062
Gentamicin 3 (3.7%) 7 (6.2%) 7 (7.1%) 11 (9%) 16 (12.6%) 15 (8.9%) 17 (5.8%) 42(10.1%) 0.0526
Netilmicin 3 (3.7%) 5 (4.4%) 7 (7.1%) 11 (9%) 19 (15%) 19 (11.3%) 15 (5.1%) 49(11.8%) 0.0022
Tetracycline 41 (51.2%) 67 (58.8%) 46 (46.9%) 62 (50.8%) 74 (58.3%) 76 (45.2%) 154(52.7%) 212(50.8%) 0.6471
Colistin 38 (47.5%) 54 (47.4%) 38 (38.8%) 48 (39.3%) 62 (48.8%) 62 (36.9%) 130 (44.5%) 172 (41.2%) 0.3968
Cotrimoxazole 9 (11.2%) 18 (15.8%) 13 (13.3%) 19 (15.6%) 31 (24.4%) 35 (20.8%) 40 (13.7%) 85 (20.4%) 0.0216
Nitrofurantoin 69 (86.2%) 96 (84.2%) 76 (77.6%) 36 (29.5%) 101 (79.5%) 131 (78%) 241 (82.5%) 268 (64.3%) 0.0001
Nalidixic acid 6 (7.5%) 16 (14%) 22 (22.4%) 21 (17.2%) 27 (21.3%) 29 (17.3%) 44 (15.1%) 77 (18.5%) 0.2649
Pefloxacin 6 (7.5%) 10 (8.8%) 12 (12.2%) 14 (11.5%) 22 (17.3%) 22 (13.1%) 28 (9.6%) 58 (13.9%) 0.1014
Ofloxacin 4 (5%) 9 (7.9%) 6 (6.1%) 10 (8.2%) 16 (12.6%) 21 (12.5%) 19 (6.5%) 47 (11.3%) 0.0355
Norfloxacin 4 (5%) 6 (5.3%) 7 (7.1%) 8 (6.6%) 16 (12.6%) 22 (13.1%) 17 (5.8%) 46 (11%) 0.0161
Ciprofloxacin 4 (5%) 10 (8.8%) 6 (6.1%) 11 (9%) 16 (12.6%) 21 (12.5%) 20 (6.8%) 48 (11.5%) 0.0389
Enterococcus spp.
Antimicrobial
agent
2005, nZ 33
Resistant
2006, nZ 44
Resistant
2007, nZ 41
Resistant
2008, nZ 44
Resistant
2009, nZ 39
Resistant
2010, nZ 41
Resistant
2005e07 (A),
nZ 118
Resistant
2008e10 (B),
nZ 124
Resistant
p value A
vs. B
Ampicillin 7 (21.2%) 8 (18.2%) 6 (14.6%) 7 (15.9%) 12(30.8%) 9 (22%) 21 (17.8%) 28 (22.6%) 0.4242
Ampicillin plus
sulbactam
7 (21.2%) 8 (18.2%) 6 (14.6%) 7 (15.9%) 12 (30.8%) 9 (22%) 21 (17.8%) 28 (22.6%) 0.4242
Gentamicin (HL
resistance)
6 (18.2%) 12 (27.3% 19(46.3% 11 (25%) 7 (17.9%) 5(12.2%) 37 (31.4%) 23 (18.5%) 0.0255
Tetracycline 23 (69.7%) 27 (61.4%) 30 (73.2%) 35 (79.5%) 27 (69.2%) 27 (65.9%) 80 (67.8%) 89 (71.8%) 0.5755
Nitrofurantoin 2 (6%) 3 (6.8%) 2 (4.9%) 3 (6.8%) 3 (7.7%) 3 (7.3%) 7 (5.9%) 9 (7.3%) 0.7979
Ciprofloxacin 30 (90.9%) 39 (88.6%) 40 (97.6%) 44 (100%) 39 (100%) 37 (90.2%) 109 (92.4%) 120 (96.8%) 0.1592
Vancomycin 3 (9.1%) 0 1 (2.4%) 0 0 0 4 (3.4%) 0 0.0551
Teicoplanin 3 (9.1%) 0 1 (2.4%) 0 0 0 4 (3.4%) 0 0.0551
CAZ clavulanic acid; HLZ high level.
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Antibiotic susceptibility of uropathogens 207Regarding sex differences in the antibiotic susceptibili-
ties, much higher resistance rates of community-acquired
E coli were seen in males for ampicillin, amoxicillin plus CA,
cephalosporins, aminoglycosides, and quinolones and
borderline higher resistance rates for nitrofurantoin. Con-
cerning the other non-E coli Enterobacteriaceae, the
resistance rates were much higher in males for all tested
antibiotics except nitrofurantoin. Finally, no significant sex
differences were noted in the antibiotic susceptibility
patterns of enterococci (Table 3).Discussion
Although most antimicrobial susceptibility surveillance
studies of urinary isolates focus on hospitalized
patients,9,10 it is becoming increasingly evident that non-
susceptibility to commonly used antibiotics is a problem
not only for hospitalized but also for outpatients with UTIs.
The most remarkable finding of our study is that a signifi-
cant increase in resistance rates of E coli and other
Enterobacteriaceae has occurred in Crete in recent years
against most of the commonly used antibiotics for CA-UTIs,
with the remarkable exception of nitrofurantoin.
The successful treatment of CA-UTIs requires effective
oral antibiotics that may be increasingly difficult to identify
in case of resistant organisms. As clearly shown from
our results, within a relatively short period of time,
a substantial increase in the non-susceptibility rates of the
Gram-negative community-acquired uropathogens to most
antibiotics was noted. By contrast, susceptibility rates of
enterococci appear to be relatively stable or decreasing in
recent years.
Increasing resistance of E coli, the main causative
pathogen of CA-UTIs to ampicillin and to a lesser extent
cotrimoxazole has been demonstrated in several parts of
the world in urinary tract isolates obtained from patients
visiting general practitioners. In such areas, fluo-
roquinolones are frequently prescribed for CA-UTIs.3
Unfortunately, as shown by our results, approximately
9%e10% of E coli and 11%e18.5% of other Enter-
obacteriaceae responsible for UTIs in outpatients of our
island are already resistant to fluoroquinolones, a worri-
some observation. Fluoroquinolone resistance is increas-
ingly common in Southern Europe,3 while it remains
particularly low in Scandinavia. In a study from Norway
among 7302 E coli UTI isolates tested, only 1.2% were flu-
oroquinolone-resistant.11 In a previous study from Greece,
the non-susceptibility rate of E coli to ciprofloxacin was
2.2%.12 In another Greek study, the proportion of
community-acquired urinary isolates resistant to nor-
floxacin was 17.8% for males and 5.5% for females.10 Higher
antibiotic resistance rates in uropathogens isolated from
males have also been described by others, likely due to the
typically nonthreatening and uncomplicated nature of UTIs
in females.3,13
We did not formally study the reasons for this significant
increase in resistance to fluoroquinolones, although this
increase likely parallels the more widespread use of qui-
nolones for community infections. Even though the Greek
Drug Administration (EOF) requires culture-directed selec-
tion of fluoroquinolones for UTIs, it is clear that, ineveryday clinical practice, many clinicians inappropriately
circumvent these restrictions. Moreover, the ease of
procuring antibiotics without a prescription in Greek phar-
macies results in excessive and unreasonable use. CA-UTIs
account for a substantial proportion of antibiotic
consumption worldwide with important ecological and
economic implications, while changes in antibiotic resis-
tance rates have been observed to follow changes in
prescription practices.12 Since the completion of our study,
we have intensified our efforts to educate the community
physicians of our area about the proper use of antibiotics
for CA-UTIs, emphasizing the need for culture-directed
therapy and the need for restricted use of broad spec-
trum antibiotics, particularly quinolones.
The Surveillance Network Database of the United States
conducted a survey of antimicrobial susceptibilities of
103,223 bacterial isolates recovered from urine samples of
female outpatients.5 In this sex-specific study, resistance of
E coli isolates to cotrimoxazole varied significantly
according to geographic region, ranging from 22% in the
western United States to 10% in the Northeast. In that
study, rates of resistance to ampicillin ranged from 30% to
40% among E coli and non-E coli isolates nationwide, and
although there was significant geographic variability in
resistance to ampicillin, this was unacceptably high, i.e., >
25% throughout the country.5 This was observed in our study
as well among both E coli and non-E coli isolates, rendering
ampicillin an inappropriate first line agent for patients with
CA-UTIs.5,14
The frequency of antimicrobial resistance of E coli
isolates shows a consistent geographical gradient, being
greater in Southern Europe, particularly Spain and Portugal
than in Northern Europe.3 For example, in Granada, Spain
37% of E coli strains were resistant to amoxicillin plus CA,
33% to cotrimoxazole, and 22% to ciprofloxacin.15 Similar
results have been published from nine Spanish regions
during 2002 and 2004. E coli was the main pathogen in both
years (73% vs. 68.3%) followed by P mirabilis (7.2% vs. 6.4%)
and K pneumoniae (5.4% vs. 5.2%). Amoxicillin (58.2%e
58.7%), cotrimoxazole (30.8%e33.8%) and ciprofloxacin
(22.6%e22.7%) showed the highest resistance rates, while
fosfomycin (2.1%e2.8%) and nitrofurantoin (3.5%e5.7%)
had the lowest resistance rates.16 Unfortunately, we did
not study the in vitro susceptibility of the uropathogens of
our study to fosfomycin. In a French study of 1160 strains of
community-acquired uropathogens, fosfomycin retained
good activity against enterobacteriaceae.17
The in vitro susceptibility of our E coli isolates to
nitrofurantoin was high (resistance 4.2% in recent years).
Hence, nitrofurantoin appears to be an excellent treatment
option for uncomplicated cystitis in our region and clearly
superior to cotrimoxazole, a drug in which 20.2% of our
E coli isolates were resistant to it. Moreover, nitrofurantoin
was the most effective oral agent against enterococcal
isolates. By contrast, nitrofurantoin was not a good treat-
ment option for non-E coli Enterobacteriaceae, such as P
mirabilis, K pneumoniae, or P aeruginosa, something
previously shown by others.18 Nitrofurantoin has been
shown to be a better empirical therapy for primary UTIs in
Sao Paulo, Brazil.19 Regarding options for oral therapy for
non- E coli Gram-negative uropathogens in our area, these
were essentially limited to fluoroquinolones, even though >
Table 3 Antibiotic susceptibilities by sex and uropathogen for selected antimicrobials (E coli, other Enterobacteriaceae and
Enterococcus spp.)
E coli Males (nZ 601) Females (nZ 2161) p value
Antibiotics Resistant (%) Resistant (%)
Ampicillin 276 (45.9) 805 (37.3) 0.0001
Amoxicillin plus CA 132 (22) 298 (13.8) < 0.0001
Cephalothin 219 (36.4) 697 (32.3) 0.0562
Cefoxitin 44 (7.3) 66 (3.1) < 0.0001
Ceftriaxone 32 (5.3) 43 (2.1) < 0.0001
Amikacin 29 (4.8) 53 (2.5) 0.004
Cotrimoxazole 136 (22.6) 478 (22.1) 0.7393
Nitrofurantoin 50 (8.3) 130 (6.1) 0.0494
Ciprofloxacin 89 (14.8) 114 (5.3) < 0.0001
Other non-E coli Enterobacteriaceae Males (nZ 212) Females (nZ 496) p value
Antibiotics Resistant (%) Resistant (%)
Ampicillin 137 (64.6) 251 (50.6) 0.0007
Amoxicillin plus CA 73 (34.4) 117 (23.6) 0.004
Cephalothin 85 (40.1) 136 (27.4) 0.001
Cefoxitin 63 (29.7) 92 (18.5) 0.0014
Ceftriaxone 33 (15.6) 34 (6.9) 0.0006
Amikacin 33 (15.6) 28 (5.6) < 0.0001
Cotrimoxazole 56 (26.4) 69 (13.9) 0.0001
Nitrofurantoin 147 (69.3) 362 (72.9) 0.3614
Ciprofloxacin 35 (16.5) 33 (6.7) 0.0001
Enterococcus spp. Males (nZ 101) Females (nZ 141) p value
Antibiotics Resistant (%) Resistant (%)
Ampicillin 24 (23.8) 26 (18.4) 0.3369
Ampicillin plus sulbactam 24 (23.8) 26 (18.4) 0.3369
Gentamicin HL 29 (28.7) 31 (22) 0.2906
CAZ clavulanic acid; HLZ high level.
208 S. Maraki et al.11% of these isolates were resistant to this class of antibi-
otics in recent years.
The ECO$SENS II study determined the antimicrobial
susceptibility of community-acquired E coli urinary isolates
in unselected women aged 18e65 years over the years
2007e2008 and compared the results with those obtained in
the ECO$SENS I study (1999e2000).20 Antimicrobial
susceptibility testing of 150e200 E coli isolates per country
to 14 antimicrobials was performed by disk diffusion using
EUCAST breakpoints. With some exception, resistance to
cefadroxil (representative of oral cephalosporins), nitro-
furantoin, fosfomycin, gentamicin and third-generation
cephalosporins was < 2%. Resistance levels were higher
for amoxicillin plus CA (2%e8.9%) and ciprofloxacin (0.5%e
7.6%) and much higher to ampicillin (21.2%e34.0%), and
cotrimoxazole (14.4%e18.2%). Resistance to quinolones
(nalidixic acid from 4.3% to 10.2%, ciprofloxacin from 1.1%
to 3.9%) and trimethoprim (from 13.3% to 16.7%) increased
between the ECO$SENS I and ECO$SENS II studies.20
ESBLs are lactamases that confer bacterial resistance
to b-lactam antibiotics and aztreonam.6 We noted
a significant increase in ESBL producing strains of E coli
and Klebsiella spp. in recent years. ESBL production
substantially complicates the treatment of CA-UTIs, ever
since it severely limits the available therapeutic options.In a study from Turkey, 20.2% of E coli isolates produced
ESBL.13 ESBL production among UTI pathogens in the
community has been described in Kuwait as well,21 and for
the first time in the recent ECO$SENS II study.20 UTIs due to
ESBL-producing E coli are emerging, even in countries with
low antibiotic use like Switzerland.6
Our study is limited by the fact that we did not collect
antibiotic resistance data by age groups, e.g., patients
15e35, 35e55, or > 55 years of age, since previous studies
have shown higher resistance rates in younger individ-
uals.10 Moreover, it is a single center study; hence our
results may not be applicable to other areas of Crete.
However, due to the tertiary nature of our hospital, we
believe that our results are representative of the recent,
true antimicrobial susceptibilities of community-acquired
uropathogens in Crete, the largest Greek island. Finally,
we did not study the antibiotic prescription patterns for
CA-UTIs in our area, because the lack of automation in
many of the local pharmacies makes such a study almost
impossible to execute. Hence, we cannot prove our
hypothesis that the increasing resistance among Enter-
obacteriaceae responsible for CA-UTIs in Crete in recent
years is the result of inappropriate prescription practices,
such as the use of broad-spectrum antibiotics including
quinolones.
Antibiotic susceptibility of uropathogens 209In conclusion, there is increasing resistance of E coli and
non-E coli community-acquired uropathogens in Crete in
recent years. This is concerning because in addition to
limiting the available therapeutic options, it has serious
ecologic and financial consequences. The latter are
particularly important nowadays that Greece is facing
tremendous financial instability. Appropriate diagnostics
and optimized antibacterial therapy are vital in order to
limit this escalating antibacterial resistance. To this extent,
continuous surveillance of antimicrobial susceptibility at
the local, national and international levels remains impor-
tant for CA-UTIs.
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